Efficacy of switching to risankizumab compared with continued adalimumab treatment in patients with moderate-to-severe plaque psoriasis

被引：0
|
作者：
Ryan, C. [1 ]
Crowley, J. [2 ]
Valdecantos, W. [3 ]
Wu, T. [3 ]
Reich, K. [4 ]
机构：
[1] Univ Coll Dublin, Dublin, Ireland
[2] Bakersfield Dermatol, Bakersfield, CA USA
[3] AbbVie Inc, N Chicago, IL USA
[4] Univ Clin Hamburg Eppendorf, Skinflammat Ctr, Dermatologikum Berlin, Hamburg, Germany
来源：
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY | 2019年 / 33卷
关键词：
Cytokine; Interleukin-23;
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P031
引用
收藏
页码：20 / 21
页数：2
相关论文
共 50 条
  • [1] Efficacy of switching to risankizumab compared with continued adalimumab treatment in patients with moderate-to-severe plaque psoriasis
    Ryan, Caitriona
    Crowley, Jeffrey
    Valdecantos, Wendell
    Wu, Tianshuang
    Reich, Kristian
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB55 - AB55
  • [2] Efficacy and safety of continuous risankizumab or switching from adalimumab to risankizumab treatment in patients with moderate-to-severe plaque psoriasis: Results from the phase 3 IMMvent Trial
    Reich, Kristian
    Gooderham, Melinda
    Thaci, Diamant
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB52 - AB52
  • [3] Risankizumab in moderate-to-severe plaque psoriasis
    Serrano, Linda
    Maloney, Victoria
    Gordon, Kenneth B.
    [J]. IMMUNOTHERAPY, 2019, 11 (16) : 1357 - 1370
  • [4] Efficacy and safety of Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis: Results from the Phase 3 IMMvent trial
    Reich, K.
    Gooderham, M.
    Thaci, D.
    Crowley, J. J.
    Ryan, C.
    Kruger, J. G.
    Tsai, T.
    Flack, M.
    Gu, Y.
    Williams, D. A.
    Thompson, E. H.
    Paul, C.
    [J]. EXPERIMENTAL DERMATOLOGY, 2019, 28 (03) : E24 - E25
  • [5] Risankizumab vs. adalimumab for moderate-to-severe plaque psoriasis: a critical appraisal
    Al-Janabi, A.
    Warren, R. B.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2020, 183 (02) : 220 - 221
  • [6] Adalimumab in the treatment of moderate-to-severe chronic plaque psoriasis in patients switching from other biologics
    Sator, P.
    Richter, L.
    Saxinger, W.
    Vasiljevic, M.
    Stingl, G.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2015, 29 (09) : 1742 - 1749
  • [7] Efficacy and safety of risankizumab (RZB) compared with adalimumab (ADA) in patients with moderate-to-severe plaque psoriasis: results from the phase 3 IMMvent trial
    Reich, K.
    Gooderham, M.
    Thaci, D.
    Crowley, J. J.
    Ryan, C.
    Krueger, J. G.
    Tsai, T. -F.
    Flack, M.
    Gu, Y.
    Williams, D. A.
    Thompson, E. H. Z.
    Paul, C.
    [J]. EXPERIMENTAL DERMATOLOGY, 2018, 27 : 9 - 10
  • [8] Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis
    Papp, Kim A.
    Blauvelt, Andrew
    Bukhalo, Michael
    Gooderham, Melinda
    Krueger, James
    Lacour, Jean-Philippe
    Menter, Alan
    Philipp, Sandra
    Sofen, Howard
    Tyring, Stephen
    Berner, Beate R.
    Visvanathan, Sudha
    Pamulapati, Chandrasena
    Bennett, Nathan
    Flack, Mary
    Scholl, Paul
    Padula, Steven J.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (16): : 1551 - 1560
  • [9] Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis
    Fioranelli, Massimo
    Roccia, Maria Grazia
    Lotti, Torello
    [J]. DERMATOLOGIC THERAPY, 2017, 30 (05)
  • [10] Efficacy of risankizumab in moderate-to-severe plaque psoriasis by baseline characteristics and prior therapies
    Strober, B.
    Valdecantos, W.
    Zhan, T.
    Lambert, J.
    Menter, A.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 : 42 - 43
12345